Phase 3 Breast Cancer Trial, Recruiting NCT03829553 Sponsor: Ruijin Hospital Condition: Breast Cancer
Back to Breast Cancer

Phase 3 Breast Cancer Trial, Recruiting

NCT03829553
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged between 18 and 75 years old
  • People with invasive breast cancer in one breast only, confirmed by a tissue sample (biopsy), at a specific stage (pT1–3)
  • People who have had breast-conserving surgery (such as a lumpectomy) or a full breast removal (mastectomy)
  • People who have had or are having breast reconstruction surgery
  • People whose cancer has spread to nearby lymph nodes under the arm, confirmed by a tissue sample — including those where only the sentinel (first) lymph node was found to be positive, without full lymph node removal
  • People expected to live more than 5 years
  • People whose surgery removed the cancer with clear edges of at least 2mm around the tumour
  • People who are in good general health, as measured by a standard medical scoring system (Karnofsky Performance Status of 80 or above)
  • People whose tumour has been tested for certain markers (estrogen receptor, progesterone receptor, HER-2, and Ki67) — these tests can be done on either the breast tumour or the lymph nodes
  • People who are able and willing to provide written consent to participate

Who may not be able to join:

  • People whose cancer has spread to lymph nodes above the collarbone, to certain lymph nodes near the breastbone on the same side, or where there are remaining lymph nodes under the arm that may need an extra radiation dose (confirm with trial site)
  • People who are pregnant or breastfeeding
  • People with serious non-cancer medical conditions — for example, severe heart disease, serious heart rhythm problems, or severe lung disease — that would make radiation treatment unsafe
  • People diagnosed with another type of cancer (other than a specific type of skin cancer called basal cell carcinoma, or pre-cancerous cells of the cervix) within the 5 years before joining the trial
  • People who have cancer in both breasts at the same time, including a non-invasive type called DCIS in the other breast
  • People who have previously had radiation therapy to the chest, underarm, or neck area
  • People with an active connective tissue disease affecting blood vessels (confirm with trial site)
  • People whose cancer has spread to other parts of the body, or whose tumour is classified as T4 (a more advanced local stage)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jia-Yi Chen, Ruijin Hospital

Phone: +86-021-64370045

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
21 February 2019
Est. completion
1 December 2022

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Locoregional recurrence (LRR)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov